639 related articles for article (PubMed ID: 32133512)
1. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
3. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
5. Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.
Johanns TM; Ward JP; Miller CA; Wilson C; Kobayashi DK; Bender D; Fu Y; Alexandrov A; Mardis ER; Artyomov MN; Schreiber RD; Dunn GP
Cancer Immunol Res; 2016 Dec; 4(12):1007-1015. PubMed ID: 27799140
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.
Sun C; Nagaoka K; Kobayashi Y; Maejima K; Nakagawa H; Nakajima J; Kakimi K
Int J Cancer; 2023 Apr; 152(7):1463-1475. PubMed ID: 36451303
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral-based vaccine promotes neoantigen-specific CD8
D'Alise AM; Brasu N; De Intinis C; Leoni G; Russo V; Langone F; Baev D; Micarelli E; Petiti L; Picelli S; Fakih M; Le DT; Overman MJ; Shields AF; Pedersen KS; Shah MA; Mukherjee S; Faivre T; Delaite P; Scarselli E; Pace L
Sci Transl Med; 2022 Aug; 14(657):eabo7604. PubMed ID: 35947675
[TBL] [Abstract][Full Text] [Related]
8. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073
[TBL] [Abstract][Full Text] [Related]
9. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
10. CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma.
Mao J; Li J; Chen J; Wen Q; Cao M; Zhang F; Li B; Zhang Q; Wang Z; Zhang J; Shen J
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056897
[TBL] [Abstract][Full Text] [Related]
11. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
12. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
14. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
15. Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma.
Johanns TM; Miller CA; Liu CJ; Perrin RJ; Bender D; Kobayashi DK; Campian JL; Chicoine MR; Dacey RG; Huang J; Fritsch EF; Gillanders WE; Artyomov MN; Mardis ER; Schreiber RD; Dunn GP
Oncoimmunology; 2019; 8(4):e1561106. PubMed ID: 30906654
[TBL] [Abstract][Full Text] [Related]
16. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
17. Lymph node-targeting adjuvant/neoantigen-codelivering vaccines for combination glioblastoma radioimmunotherapy.
Su T; Zhou S; Yang S; Humble N; Zhang F; Yu G; Bos PD; Cheng F; Valerie K; Zhu G
Theranostics; 2023; 13(13):4304-4315. PubMed ID: 37649594
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]